Mutations associated with lamivudine-resistance in therapy-naïve Hepatitis B Virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected South African patients

Journal of Medical Virology

Volumn 79, Issue 11, 2007, Pages 1650-1654

  Selabe, S Gloria ^a   Lukhwareni, Azwidowi ^a   Song, Ernest ^b   Leeuw, Yeegan G M ^c   Burnett, Rosemary J ^a   Mphahlele, M Jeffrey ^a,d  

^a UNIVERSITY OF LIMPOPO   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c Margarita Health Centre   (South Africa)

^d SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

Author keywords

HBV HIV co infection; Hepatitis V virus; Human immunodeficiency virus; Lamivudine resistant HBV strains; Sub Saharan Africa

Indexed keywords

ASPARTIC ACID; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; METHIONINE; TYROSINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; FEMALE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NUCLEOTIDE SEQUENCE; PROTEIN MOTIF; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTH AFRICA; VIRUS CARRIER; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

AMINO ACID MOTIFS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34748835493     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20974     Document Type: Article

References (28)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolon P. 1996. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 125:705-712.
3. Besisik F, Karaca C, Akyuz F, Horosanli S, Onel D, Badur S, Sever MS, Danalioglu A, Demir K, Kaymakoglu S, Cakaloglu Y, Okten A. 2003. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 38:506-510.
4. Burnett RJ, Ngobeni JM, François G, Hoosen AA, Leroux-Roels G, Meheus A, Mphahlele MJ. 2007. Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women. Int J STD AIDS 2007. 18:152-156.
5. Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S, Sasadeusz J. 2003. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 17:1649-1657.
6. Corpet F. 1988. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16:10881-10890.
7. Dore GJ, Cooper DA, Barret C, Goh LE, Thakrar B, Atkins M. 1999. For the CAESAR coordinating committee dual efficacy of lamivudine treatment in human immunodeficiency virus/ hepatitis B virus co-infected persons in a randomized controlled study (CAESAR). J Infect Dis 180:607-613.
8. Gutfreund KS, Williams M, George R, Bain VG, Ma MM, Yoshida EM, Villeneuve JP, Fischer KP, Tyrrel DL. 2000. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 33:469-475.
9. Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US. 2004. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci 19:541-546.
10. Kashala O, Mubikayi L, Kayembe K., et al. 1994. Hepatitis B virus activation among Central Africans infected with human immunodeficiency virus (HIV) type I: Pre-s2 antigen is predominantly expressed in HIV infection. J Infect Dis 169:628-632.
11. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. 2003. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 188:571-577.
12. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, Toyama T, Minami M. 2002. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 37:259-265.
13. Kobayashi S, Ide T, Sata M. 2001. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 34:584-586.
14. Lodenyo H, Schoun B, Ally R, Kairu S, Segal I. 2000. Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. East Afr Med J 77:13-15.
15. Lukhwareni A, Mphahlele MK, Ramulifho TE, Mphahlele MJ. 2006. Hepatitis B virus, hepatitis c virus and human immunodeficiency viruses co-infections in patients receiving antiretroviral drugs at Dr George Mukhari hospital, South Africa. Eighth international congress on drug therapy in HIV infection, Glasgow, UK, 12-16 November 2006.
16. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. 2006. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 35:14-20.
17. Mutimer D, Dusheiko G, Barrett C, Grellier I, Ahmed M, Anschuetz G, Burroughs A, Hubscher S, Dhillon AP, Rolles K, Elias E. 2000. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up. Transplantation 70:809-815.
18. Niesters HG, Honkoop P, Haagsma EB, De Man RA, Schalm SW, Osterhaus AD. 1998. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 177:1382-1385.
19. Ohishi W, Shirakawa H, Kawakami Y, Kimura S, Kamiyasu M, Tazuma S, Nakanishi T, Chayama K. 2004. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping. J Med Virol 72:558-565.
20. Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM. 2006. The clinical impact of early detection of the YMMD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antivir Ther 11:447-455.
21. Scharschmidt BF, Held MJ, Hollander HH, Read AE, Lavine JE, Veereman G, McGuire RF, Thaler MM. 1992. Hepatitis B in Patients with HIV Infection: Relationship to AIDS and Patient Survival. Ann Intern Med 117:837-838.
22. Sinicco A, Raiteri R, Sciandra M, Bertone C, Lingua A, Salassa B, Gioannini P. 1997. Co-infection and super-infection of Hepatitis B virus in patients infected with immunodeficiency virus: No evidence of faster progression to AIDS. Scand J Infect Dis 29:111-115.
23. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R. 2001. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 38:702-707.
24. Thibault V, Benhamou Y, Seguret C, Bochet M, Katlama C, Bricaire F, Opolon P, Poynard T, Agut H. 1999. Hepatitis B Virus (HBV) Mutations Associated with Resistance to Lamivudine in Patients Co-infected with HBV and Human Immunodeficiency Virus. J Clin Microbiol 37:3013-3016.
25. Thibault V, Aubron-Olivier C, Agut H, Katlama C. 2002. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 16:131-133.
26. Thio CL. 2004. Chronic hepatitis B or C in HIV-infected persons: Pathogenesis and management. J Gastroenterol Hepatol 19: S138.
27. Thio CL, Seaberg EC, Skolasky R, Jr, Phair J, Visscher B, Munoz A, Thomas DL, Multicenter AIDS cohort study. 2002. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360:1921-1926.
28. Wolters LM, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, Brinkman K, Meenhorst PL, de Man RA. 2002. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 24:173-181.